Jacques Fourgeaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacques Fourgeaud has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Marianne Leruez-Ville
Université Paris Cité, URP 7328 FETUS, F-75015 Paris, France; Virology Laboratory, Reference Laboratory for Herpes Virus, AP-HP, Hospital Necker-Enfants malades, 75015 Paris, France
7 shared publications Tiffany Guilleminot
Virology Unit – National reference laboratory for herpes viruses - Hôpital Necker Enfants Malades, AP-HP, Hôpital Necker Enfants Malades
5 shared publicationsYves Ville
Université Paris Cité, FETUS
5 shared publications- Nicolas Bourgon
Imagine Institute, Genetics and Development of the Cerebral Cortex INSERM UMR 1163, Université Paris Cité Paris France
4 shared publications - Pierre Frange
Microbiology department, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Université Paris Cité, URP 7328 FETUS, Paris, France
4 shared publications Laurence Bussières
Obstetrics and Fetal Medicine Unit—Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP , Paris
3 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (9)
Comparative performance of CMV IgM and IgG avidity assays for diagnosing a recent primary infection in the first trimester of pregnancy
First-trimester (T1) cytomegalovirus (CMV) screening relies on IgG, IgM, and IgG avidity testing, but assay performance may vary according to the infection timing. To evaluate the ability of two IgM and three IgG avidity assays to detect maternal primary CMV infection (MPI) occurring in T1 or the periconceptional period. We analyzed 176 serum samples from 94 pregnant women with precisely dated MPI based on seroconversion. Samples were tested using two IgM assays (LIAISON CMV IgM II, Alinity i CMV IgM) and three IgG avidity assays (VIDAS CMV IgG Avidity II, LIAISON CMV IgG Avidity II, Alinity i CMV IgG avidity). For detection of MPI within 4 months, the IgM sensitivity was 99% (122/123) with LIAISON and 92% (94/102) with Alinity i. IgG avidity sensitivity for excluding MPI <4 months was 99% (124/125) with LIAISON, 98% (121/123) with VIDAS, and 92% (111/120) with Alinity i. The positive predictive value of low avidity was highest with VIDAS, followed by LIAISON and Alinity i. Retesting intermediate-avidity results with a second assay improved the estimation of MPI timing. All three avidity assays reliably excluded T1 MPI. Alinity i showed reduced sensitivity for ruling out periconceptional infection, supporting confirmatory testing in equivocal cases. IMPORTANCE: In the context of universal first-trimester cytomegalovirus (CMV) screening and the demonstrated efficacy of valacyclovir to prevent vertical transmission, reliable identification of recent maternal primary infection has become crucial. In this study, we compared the performance of two CMV IgM kits (LIAISON CMV IgM II [DiaSorin]; Alinity i CMV IgM [Abbott Diagnostics]) and three CMV IgG avidity kits (LIAISON CMV IgG Avidity II [DiaSorin]; VIDAS CMV IgG Avidity II [Biomérieux]; Alinity i CMV IgG avidity [Abbott Diagnostics]). Our study assesses the performance of commonly used CMV IgM and IgG avidity assays in a large cohort of pregnant women with precisely dated primary infections, a setting rarely available for assay validation. We provide gestational age-specific performance data and highlight the limited positive predictive value of intermediate-IgG avidity results. Based on these findings, we propose a pragmatic diagnostic algorithm aimed at reducing misclassification and inappropriate clinical management.
- 9 September 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (9)
Open AccessComparative performance of CMV IgM and IgG avidity assays for diagnosing a recent primary infection in the first trimester of pregnancy
First-trimester (T1) cytomegalovirus (CMV) screening relies on IgG, IgM, and IgG avidity testing, but assay performance may vary according to the infection timing. To evaluate the ability of two IgM and three IgG avidity assays to detect maternal primary CMV infection (MPI) occurring in T1 or the periconceptional period. We analyzed 176 serum samples from 94 pregnant women with precisely dated MPI based on seroconversion. Samples were tested using two IgM assays (LIAISON CMV IgM II, Alinity i CMV IgM) and three IgG avidity assays (VIDAS CMV IgG Avidity II, LIAISON CMV IgG Avidity II, Alinity i CMV IgG avidity). For detection of MPI within 4 months, the IgM sensitivity was 99% (122/123) with LIAISON and 92% (94/102) with Alinity i. IgG avidity sensitivity for excluding MPI <4 months was 99% (124/125) with LIAISON, 98% (121/123) with VIDAS, and 92% (111/120) with Alinity i. The positive predictive value of low avidity was highest with VIDAS, followed by LIAISON and Alinity i. Retesting intermediate-avidity results with a second assay improved the estimation of MPI timing. All three avidity assays reliably excluded T1 MPI. Alinity i showed reduced sensitivity for ruling out periconceptional infection, supporting confirmatory testing in equivocal cases. IMPORTANCE: In the context of universal first-trimester cytomegalovirus (CMV) screening and the demonstrated efficacy of valacyclovir to prevent vertical transmission, reliable identification of recent maternal primary infection has become crucial. In this study, we compared the performance of two CMV IgM kits (LIAISON CMV IgM II [DiaSorin]; Alinity i CMV IgM [Abbott Diagnostics]) and three CMV IgG avidity kits (LIAISON CMV IgG Avidity II [DiaSorin]; VIDAS CMV IgG Avidity II [Biomérieux]; Alinity i CMV IgG avidity [Abbott Diagnostics]). Our study assesses the performance of commonly used CMV IgM and IgG avidity assays in a large cohort of pregnant women with precisely dated primary infections, a setting rarely available for assay validation. We provide gestational age-specific performance data and highlight the limited positive predictive value of intermediate-IgG avidity results. Based on these findings, we propose a pragmatic diagnostic algorithm aimed at reducing misclassification and inappropriate clinical management.
- 28 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (2) , e218253
Teaching NeuroImage: Chronic Hepatitis E-Associated Myelitis in an Immunocompromised Patient
- 28 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (2) , e218253
Teaching NeuroImage: Chronic Hepatitis E-Associated Myelitis in an Immunocompromised Patient
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification de virus impliqués dans les pathologies inexpliquées du patient immunodéprimé
Les patients présentant un déficit immunitaire primitif ou secondaire peuvent être infectés par un large panel de pathogènes, opportunistes ou non, entrainant des symptômes parfois atypiques et avec une expression clinique retardée suite à la primo-infection, ce qui rend le diagnostic de ces infections particulièrement difficile. Bien que les techniques de culture ou de PCR universelle pour le diagnostic des infections bactériennes soient souvent à large spectre, la recherche de virus est ciblée, ce qui limite la liste des virus détectables aux virus pathogènes les plus communs. Dans ce contexte, certaines pathologies qui pourraient avoir une étiologie virale restent inexpliquées. La métagénomique (mNGS) permet l'identification non ciblée d'un large éventail d'agents pathogènes, y compris les virus rares ou nouveaux qui ne sont pas détectés avec les techniques conventionnelles. L'analyse mNGS est reconnue comme un outil de diagnostic précieux, cependant les performances de cette analyse dans le cadre du soin et ses indications les plus pertinentes sont mal définies. L'objectif de cette étude est d'identifier des virus impliqués dans certaines pathologies inexpliquées notamment hépatiques du patient immunodéprimé par mNGS et d'identifier des indications de l'analyse mNGS pour le diagnostic des infections virales. Dans la première partie de ce travail, nous avons mis en évidence une nouvelle pathologie associée à Aichi virus chez six patients présentant un déficit immunitaire primitif. Nous avons également apporté un faisceau d'arguments en faveur du lien causal entre l'infection persistante par le virus et la pathologie hépatique chronique, grâce à la mise au point de techniques de RT-PCR, d'hybridation in situ et de génotypage à façon. Dans la deuxième partie de ce travail nous avons identifié un nouveau Circovirus, Human circovirus 1, chez une patiente adulte greffée cœur-poumon présentant une hépatite aiguë inexpliquée. Nous avons également exploré le lien causal entre ce virus et la pathologie en développant des techniques moléculaires à façon. Enfin dans la troisième partie de ce travail, nous avons analysé les résultats de trois années d'activité de mNGS réalisée prospectivement dans le cadre du diagnostic dans notre centre. Cette étude nous a permis d'identifier un intérêt diagnostic majeur du mNGS chez les patients immunodéprimés (i) pour la détection de pathogènes opportunistes, (ii) en cas de symptômes atypiques ou (iii) dans le cas du diagnostic différentiel avec une pathologie inflammatoire ou dysimmunitaire. Cette étude nous a aussi permis de classer les prélèvements en fonction de leur rentabilité diagnostique pour l'analyse par mNGS, élevée pour les selles et faible pour le liquide céphalorachidien. En effet nous avons montré l'intérêt de l'analyse par mNGS des tissus cérébraux par rapport au liquide céphalorachidien en cas de symptômes neurologiques inexpliqués. L'analyse des selles par mNGS chez des patients présentant un déficit immunitaire primitif et des hépatites inexpliquées pourrait également être une indication de l'analyse mNGS. L'ensemble de ce travail a permis d'affiner le positionnement du mNGS au sein de l'arsenal disponible pour le diagnostic des infections virales.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification de virus impliqués dans les pathologies inexpliquées du patient immunodéprimé
Les patients présentant un déficit immunitaire primitif ou secondaire peuvent être infectés par un large panel de pathogènes, opportunistes ou non, entrainant des symptômes parfois atypiques et avec une expression clinique retardée suite à la primo-infection, ce qui rend le diagnostic de ces infections particulièrement difficile. Bien que les techniques de culture ou de PCR universelle pour le diagnostic des infections bactériennes soient souvent à large spectre, la recherche de virus est ciblée, ce qui limite la liste des virus détectables aux virus pathogènes les plus communs. Dans ce contexte, certaines pathologies qui pourraient avoir une étiologie virale restent inexpliquées. La métagénomique (mNGS) permet l'identification non ciblée d'un large éventail d'agents pathogènes, y compris les virus rares ou nouveaux qui ne sont pas détectés avec les techniques conventionnelles. L'analyse mNGS est reconnue comme un outil de diagnostic précieux, cependant les performances de cette analyse dans le cadre du soin et ses indications les plus pertinentes sont mal définies. L'objectif de cette étude est d'identifier des virus impliqués dans certaines pathologies inexpliquées notamment hépatiques du patient immunodéprimé par mNGS et d'identifier des indications de l'analyse mNGS pour le diagnostic des infections virales. Dans la première partie de ce travail, nous avons mis en évidence une nouvelle pathologie associée à Aichi virus chez six patients présentant un déficit immunitaire primitif. Nous avons également apporté un faisceau d'arguments en faveur du lien causal entre l'infection persistante par le virus et la pathologie hépatique chronique, grâce à la mise au point de techniques de RT-PCR, d'hybridation in situ et de génotypage à façon. Dans la deuxième partie de ce travail nous avons identifié un nouveau Circovirus, Human circovirus 1, chez une patiente adulte greffée cœur-poumon présentant une hépatite aiguë inexpliquée. Nous avons également exploré le lien causal entre ce virus et la pathologie en développant des techniques moléculaires à façon. Enfin dans la troisième partie de ce travail, nous avons analysé les résultats de trois années d'activité de mNGS réalisée prospectivement dans le cadre du diagnostic dans notre centre. Cette étude nous a permis d'identifier un intérêt diagnostic majeur du mNGS chez les patients immunodéprimés (i) pour la détection de pathogènes opportunistes, (ii) en cas de symptômes atypiques ou (iii) dans le cas du diagnostic différentiel avec une pathologie inflammatoire ou dysimmunitaire. Cette étude nous a aussi permis de classer les prélèvements en fonction de leur rentabilité diagnostique pour l'analyse par mNGS, élevée pour les selles et faible pour le liquide céphalorachidien. En effet nous avons montré l'intérêt de l'analyse par mNGS des tissus cérébraux par rapport au liquide céphalorachidien en cas de symptômes neurologiques inexpliqués. L'analyse des selles par mNGS chez des patients présentant un déficit immunitaire primitif et des hépatites inexpliquées pourrait également être une indication de l'analyse mNGS. L'ensemble de ce travail a permis d'affiner le positionnement du mNGS au sein de l'arsenal disponible pour le diagnostic des infections virales.
- Open Access
- 10 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1491-1494
Occult rat hepatitis E virus infection as a cause of cirrhosis and posttransplant recurrence: Insights into the role of metagenomics
- 10 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1491-1494
Open AccessOccult rat hepatitis E virus infection as a cause of cirrhosis and posttransplant recurrence: Insights into the role of metagenomics
- 1 December 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (6) , e200558
Diagnostic Yield of Next-Generation Sequencing in CSF or Brain Biopsy for Severe Encephalitis Requiring Intensive Care
The aim of this study was to evaluate the contribution of metagenomic next-generation sequencing (mNGS) in critically ill patients with encephalitis of unknown etiology. This retrospective study (2016-2023) was conducted in a tertiary care referral neuro-ICU at La Pitié-Salpêtrière Hospital (Paris, France). The inclusion criteria were encephalitis with unknown etiology and mNGS performed on CSF, brain biopsy, and/or autopsy. We assessed the yield of mNGS and whether specific treatments were initiated. Neurologic outcome at 1 year was assessed using the Glasgow Outcome Scale-Extended (GOSE-1: death; GOSE-8: upper good recovery). A total of 49 patients were included, of whom 44.9% were immunosuppressed. At 1 year, 38.8% had a GOSE score 4-8 and 47.7% died. mNGS was performed on the CSF of 40 of 49 patients (81.6%) and on brain biopsy of 19 of 49 patients (38.8%), including 12 patients who underwent both CSF and biopsy testing. Among the 40 mNGS analyses performed on the CSF, 7 (17.5%) yielded positive results but only 1 (2.5%) was likely causative. Conversely, 7 of 19 mNGS analyses (36.8%) on biopsies were positive and causative. Regarding the yield of mNGS in the entire cohort, 15 of 49 patients (30.6%) had a positive result but only 7 of 49 (14.3%) were causative (dengue virus, measles virus, rubella virus, Nocardia spp, HHV6, astrovirus, and orthobunyavirus), all from brain biopsies of immunocompromised patients. Conversely, 8 of 49 mNGS analyses (16.3%) were noncausative (polyomavirus, HHV8, HHV7, EBV, 2 pegiviruses, and 2 rhinoviruses). Specific treatments were initiated in 4 of 7 patients (57%). Among the 34 patients with a negative mNGS result, 5 (14.7%) were diagnosed with infectious encephalitis using conventional methods. In critically ill patients with encephalitis of unknown etiology, mNGS performed on brain biopsy could reduce diagnostic uncertainty.
- 1 December 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (6) , e200558
Diagnostic Yield of Next-Generation Sequencing in CSF or Brain Biopsy for Severe Encephalitis Requiring Intensive Care
The aim of this study was to evaluate the contribution of metagenomic next-generation sequencing (mNGS) in critically ill patients with encephalitis of unknown etiology. This retrospective study (2016-2023) was conducted in a tertiary care referral neuro-ICU at La Pitié-Salpêtrière Hospital (Paris, France). The inclusion criteria were encephalitis with unknown etiology and mNGS performed on CSF, brain biopsy, and/or autopsy. We assessed the yield of mNGS and whether specific treatments were initiated. Neurologic outcome at 1 year was assessed using the Glasgow Outcome Scale-Extended (GOSE-1: death; GOSE-8: upper good recovery). A total of 49 patients were included, of whom 44.9% were immunosuppressed. At 1 year, 38.8% had a GOSE score 4-8 and 47.7% died. mNGS was performed on the CSF of 40 of 49 patients (81.6%) and on brain biopsy of 19 of 49 patients (38.8%), including 12 patients who underwent both CSF and biopsy testing. Among the 40 mNGS analyses performed on the CSF, 7 (17.5%) yielded positive results but only 1 (2.5%) was likely causative. Conversely, 7 of 19 mNGS analyses (36.8%) on biopsies were positive and causative. Regarding the yield of mNGS in the entire cohort, 15 of 49 patients (30.6%) had a positive result but only 7 of 49 (14.3%) were causative (dengue virus, measles virus, rubella virus, Nocardia spp, HHV6, astrovirus, and orthobunyavirus), all from brain biopsies of immunocompromised patients. Conversely, 8 of 49 mNGS analyses (16.3%) were noncausative (polyomavirus, HHV8, HHV7, EBV, 2 pegiviruses, and 2 rhinoviruses). Specific treatments were initiated in 4 of 7 patients (57%). Among the 34 patients with a negative mNGS result, 5 (14.7%) were diagnosed with infectious encephalitis using conventional methods. In critically ill patients with encephalitis of unknown etiology, mNGS performed on brain biopsy could reduce diagnostic uncertainty.
- 6 October 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (5) , 598-605
Non‐invasive prenatal diagnosis of congenital cytomegalovirus infection using maximum trophoblast thickness and biomarkers in maternal blood and urine in first trimester
Objective: Congenital cytomegalovirus (CMV) infection, a leading cause of sensorineural hearing loss and neurological impairment, is typically diagnosed by second‐trimester amniocentesis, delaying clinical decision‐making. This study aimed to assess the predictive value of maximum trophoblast thickness (MTT) measured by first‐trimester three‐dimensional (3D) ultrasound, in combination with maternal biomarkers, for the early prediction of CMV vertical transmission. Methods: This was a retrospective cohort study of pregnant women, not previously seropositive for CMV, who were referred to Necker–Enfants malades Hospital between October 2019 and May 2024 for maternal primary infection (MPI) with CMV in early pregnancy. Multiple pregnancies and fetuses with genetic anomaly were excluded. MTT measurement was performed using 3D multiplanar ultrasound between 11 + 0 and 14 + 6 weeks' gestation by two independent observers. Interobserver agreement for MTT measurement was assessed using the intraclass correlation coefficient (ICC). We recorded maternal characteristics, including first‐trimester maternal biomarkers (pregnancy‐associated plasma protein‐A, free β‐human chorionic gonadotropin and placental growth factor) and CMV polymerase chain reaction (PCR) status in the maternal blood and urine. Vertical transmission was confirmed by CMV‐PCR in chorionic villi (CV) and/or amniotic fluid (AF). The predictive value of MTT, alone and in combination with relevant covariables, was assessed using logistic regression models and receiver‐operating‐characteristics (ROC)‐curve analysis. Results: A total of 127 pregnant women with a median gestational age (GA) at CMV‐MPI of 2.0 (interquartile range, −2.5 to 7.0) weeks were included, of whom 120 (94.5%) received valacyclovir for secondary prevention. CMV‐PCR was positive in 7.1% of CV samples (median GA at sampling, 13.7 weeks) and 9.4% of AF samples (median GA at sampling, 17.4 weeks). MTT was significantly higher in cases with a positive CMV‐PCR result in AF compared to those with a negative result (median, 21.3 mm vs 17.1 mm; P = 0.017). The ICC for MTT measurement was 0.827 (95% CI, 0.763–0.875), indicating good interobserver reproducibility. ROC‐curve analysis identified 19.0 mm as the optimal MTT threshold, yielding a sensitivity of 83.33% (95% CI, 62.25–100%) for predicting vertical transmission. When combined with CMV‐PCR positivity in the maternal blood in the first trimester and delayed valacyclovir initiation beyond 10 weeks, the predictive model achieved an area under the ROC curve of 0.94 (95% CI, 0.87–0.99) for CMV‐PCR positivity in AF, with a sensitivity of 80.00% (95% CI, 44.39–97.48%), specificity of 93.26% (95% CI, 85.90–97.49%), positive predictive value of 57.14% (95% CI, 36.71–75.40%) and negative predictive value of 97.65% (95% CI, 92.31–99.31%). Conclusion: Increased MTT measured by 3D ultrasound in the first trimester is associated with CMV vertical transmission and may serve as an early non‐invasive marker. Combining MTT with CMV‐PCR status in the maternal blood and timing at initiation of treatment improves predictive accuracy and could guide early counseling and targeted invasive testing. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
- 6 October 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (5) , 598-605
Non‐invasive prenatal diagnosis of congenital cytomegalovirus infection using maximum trophoblast thickness and biomarkers in maternal blood and urine in first trimester
Objective: Congenital cytomegalovirus (CMV) infection, a leading cause of sensorineural hearing loss and neurological impairment, is typically diagnosed by second‐trimester amniocentesis, delaying clinical decision‐making. This study aimed to assess the predictive value of maximum trophoblast thickness (MTT) measured by first‐trimester three‐dimensional (3D) ultrasound, in combination with maternal biomarkers, for the early prediction of CMV vertical transmission. Methods: This was a retrospective cohort study of pregnant women, not previously seropositive for CMV, who were referred to Necker–Enfants malades Hospital between October 2019 and May 2024 for maternal primary infection (MPI) with CMV in early pregnancy. Multiple pregnancies and fetuses with genetic anomaly were excluded. MTT measurement was performed using 3D multiplanar ultrasound between 11 + 0 and 14 + 6 weeks' gestation by two independent observers. Interobserver agreement for MTT measurement was assessed using the intraclass correlation coefficient (ICC). We recorded maternal characteristics, including first‐trimester maternal biomarkers (pregnancy‐associated plasma protein‐A, free β‐human chorionic gonadotropin and placental growth factor) and CMV polymerase chain reaction (PCR) status in the maternal blood and urine. Vertical transmission was confirmed by CMV‐PCR in chorionic villi (CV) and/or amniotic fluid (AF). The predictive value of MTT, alone and in combination with relevant covariables, was assessed using logistic regression models and receiver‐operating‐characteristics (ROC)‐curve analysis. Results: A total of 127 pregnant women with a median gestational age (GA) at CMV‐MPI of 2.0 (interquartile range, −2.5 to 7.0) weeks were included, of whom 120 (94.5%) received valacyclovir for secondary prevention. CMV‐PCR was positive in 7.1% of CV samples (median GA at sampling, 13.7 weeks) and 9.4% of AF samples (median GA at sampling, 17.4 weeks). MTT was significantly higher in cases with a positive CMV‐PCR result in AF compared to those with a negative result (median, 21.3 mm vs 17.1 mm; P = 0.017). The ICC for MTT measurement was 0.827 (95% CI, 0.763–0.875), indicating good interobserver reproducibility. ROC‐curve analysis identified 19.0 mm as the optimal MTT threshold, yielding a sensitivity of 83.33% (95% CI, 62.25–100%) for predicting vertical transmission. When combined with CMV‐PCR positivity in the maternal blood in the first trimester and delayed valacyclovir initiation beyond 10 weeks, the predictive model achieved an area under the ROC curve of 0.94 (95% CI, 0.87–0.99) for CMV‐PCR positivity in AF, with a sensitivity of 80.00% (95% CI, 44.39–97.48%), specificity of 93.26% (95% CI, 85.90–97.49%), positive predictive value of 57.14% (95% CI, 36.71–75.40%) and negative predictive value of 97.65% (95% CI, 92.31–99.31%). Conclusion: Increased MTT measured by 3D ultrasound in the first trimester is associated with CMV vertical transmission and may serve as an early non‐invasive marker. Combining MTT with CMV‐PCR status in the maternal blood and timing at initiation of treatment improves predictive accuracy and could guide early counseling and targeted invasive testing. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 6 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e417-e423
Cytomegalovirus Vertical Transmission Rate According to IgG Avidity Value and Valacyclovir Treatment of Maternal Primary Infection in the First Trimester of Pregnancy
Background: Cytomegalovirus (CMV) serology in the first trimester (T1) of pregnancy relies on immunoglobulin (Ig) G (IgG) and IgM testing, followed by IgG avidity measurement when both IgG and IgM are positive. Valacyclovir is proposed to prevent vertical transmission in maternal primary infection (MPI) during T1. Our objective was to assess the risk of transmission, with and without valacyclovir, based on IgG avidity values and MPI timing. Methods: Cases (2012–2024) with positive or equivocal IgM, intermediate or low IgG avidity (VIDAS and/or LIAISON) in T1, and a CMV PCR performed in amniotic fluid were retrieved from the laboratory software. The MPI date was estimated using a logarithmic model based on VIDAS avidity results. Results: Five hundred and sixty one women (58% untreated, 42% treated) were included. In cases with low avidity and no treatment, transmission was 34% and 31% with VIDAS and LIAISON assays, respectively. Intermediate avidities and no treatment were also associated with high transmission rates (14% and 22%). VIDAS avidity values ≥0.60 or ≥0.50 in samples collected before 12 weeks were associated with 0% and 5% transmission rates, respectively. Without treatment, transmission occurred in 26% (9/34) of women with a LIAISON avidity value between 0.250 and 0.350. Valacyclovir significantly reduced transmission to 2%, 5%, and 16% in preconceptional, periconceptional, and T1 periods, respectively (P = .034, .003, and <.001). Conclusions: Our results suggest that the LIAISON threshold for high avidity should be >0.250. Except for VIDAS avidity values ≥0.60 before 12 weeks, treatment is beneficial for women with positive IgM and low/intermediate avidity, regardless of MPI timing.
- 6 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e417-e423
Open AccessCytomegalovirus Vertical Transmission Rate According to IgG Avidity Value and Valacyclovir Treatment of Maternal Primary Infection in the First Trimester of Pregnancy
Background: Cytomegalovirus (CMV) serology in the first trimester (T1) of pregnancy relies on immunoglobulin (Ig) G (IgG) and IgM testing, followed by IgG avidity measurement when both IgG and IgM are positive. Valacyclovir is proposed to prevent vertical transmission in maternal primary infection (MPI) during T1. Our objective was to assess the risk of transmission, with and without valacyclovir, based on IgG avidity values and MPI timing. Methods: Cases (2012–2024) with positive or equivocal IgM, intermediate or low IgG avidity (VIDAS and/or LIAISON) in T1, and a CMV PCR performed in amniotic fluid were retrieved from the laboratory software. The MPI date was estimated using a logarithmic model based on VIDAS avidity results. Results: Five hundred and sixty one women (58% untreated, 42% treated) were included. In cases with low avidity and no treatment, transmission was 34% and 31% with VIDAS and LIAISON assays, respectively. Intermediate avidities and no treatment were also associated with high transmission rates (14% and 22%). VIDAS avidity values ≥0.60 or ≥0.50 in samples collected before 12 weeks were associated with 0% and 5% transmission rates, respectively. Without treatment, transmission occurred in 26% (9/34) of women with a LIAISON avidity value between 0.250 and 0.350. Valacyclovir significantly reduced transmission to 2%, 5%, and 16% in preconceptional, periconceptional, and T1 periods, respectively (P = .034, .003, and <.001). Conclusions: Our results suggest that the LIAISON threshold for high avidity should be >0.250. Except for VIDAS avidity values ≥0.60 before 12 weeks, treatment is beneficial for women with positive IgM and low/intermediate avidity, regardless of MPI timing.
- 26 June 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (2) , 248-250
Cytomegalovirus universal screening in early pregnancy: truth is a tendency
- 26 June 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 66 (2) , 248-250
Cytomegalovirus universal screening in early pregnancy: truth is a tendency
- 10 April 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 65 (5) , 653-655
Metagenomic analysis of NIPT raw data suggests high negative predictive value for congenital cytomegalovirus infection screening
- 10 April 2025
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 65 (5) , 653-655
Metagenomic analysis of NIPT raw data suggests high negative predictive value for congenital cytomegalovirus infection screening
- Open Access
- 20 March 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70314
Remdesivir for the Treatment of Human Coronavirus OC43 Encephalitis
Human coronavirus OC43 (HCoV‐OC43) is predominantly associated with mild respiratory infections. HCoV‐OC43 also has neuroinvasive properties, and severe encephalitis has been described in immunocompromised patients, with fatal outcomes due to the lack of specific antiviral treatment. We report a case of severe febrile encephalitis attributed to HCoV‐OC43 that progressively worsened over 3 months in a 65‐year‐old immunocompromised man. Clinical symptoms improved remarkably after treatment with remdesivir, with an increase of the Glasgow Coma Score from 8 to 14 within 7 days.
- 20 March 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70314
Open AccessRemdesivir for the Treatment of Human Coronavirus OC43 Encephalitis
Human coronavirus OC43 (HCoV‐OC43) is predominantly associated with mild respiratory infections. HCoV‐OC43 also has neuroinvasive properties, and severe encephalitis has been described in immunocompromised patients, with fatal outcomes due to the lack of specific antiviral treatment. We report a case of severe febrile encephalitis attributed to HCoV‐OC43 that progressively worsened over 3 months in a 65‐year‐old immunocompromised man. Clinical symptoms improved remarkably after treatment with remdesivir, with an increase of the Glasgow Coma Score from 8 to 14 within 7 days.